Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Elwood

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Pharmacogenomics|September 19, 2009
Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse populationSo Yamada, Mila Tang, Kathryn Richardson, et al.
Annals of Internal Medicine|June 17, 2020
Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different SettingsMayara Lisboa Bastos, Jonathon R Campbell, Olivia Oxlade, et al.
The New England Journal of Medicine|August 2, 2018
Safety and Side Effects of Rifampin versus Isoniazid in ChildrenThierno Diallo, Menonli Adjobimey, Rovina Ruslami, et al.
The New England Journal of Medicine|February 25, 2011
Whole-genome sequencing and social-network analysis of a tuberculosis outbreakJennifer L Gardy, James C Johnston, Shannan J Ho Sui, et al.
Journal of Clinical Immunology|September 1, 2005
Primary immune deficiencies presenting in adults: seven years of experience from IranDavood Mansouri, Parisa Adimi, Mehdi Mirsaedi, et al.
The New England Journal of Medicine|August 2, 2018
Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in AdultsDick Menzies, Menonli Adjobimey, Rovina Ruslami, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 14, 2025
A rare variant in <i>GPR156</i> associated with depression in a Mennonite pedigree causes habenula hyperactivity and stress sensitivity in miceBradley R Miller, Claudia Gonzaga-Jauregui, Karlla W Brigatti, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Pharmacogenomics|September 19, 2009
Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse populationSo Yamada, Mila Tang, Kathryn Richardson, et al.
Annals of Internal Medicine|June 17, 2020
Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different SettingsMayara Lisboa Bastos, Jonathon R Campbell, Olivia Oxlade, et al.
The New England Journal of Medicine|August 2, 2018
Safety and Side Effects of Rifampin versus Isoniazid in ChildrenThierno Diallo, Menonli Adjobimey, Rovina Ruslami, et al.
The New England Journal of Medicine|February 25, 2011
Whole-genome sequencing and social-network analysis of a tuberculosis outbreakJennifer L Gardy, James C Johnston, Shannan J Ho Sui, et al.
Journal of Clinical Immunology|September 1, 2005
Primary immune deficiencies presenting in adults: seven years of experience from IranDavood Mansouri, Parisa Adimi, Mehdi Mirsaedi, et al.
The New England Journal of Medicine|August 2, 2018
Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in AdultsDick Menzies, Menonli Adjobimey, Rovina Ruslami, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 14, 2025
A rare variant in <i>GPR156</i> associated with depression in a Mennonite pedigree causes habenula hyperactivity and stress sensitivity in miceBradley R Miller, Claudia Gonzaga-Jauregui, Karlla W Brigatti, et al.
Pageof 3